Does CANF pay dividends?

Can Fite Biopharma Ltd ADR (CANF) has a dividend payment track record. See the CANF dividend history page for its current payment status, yield, and streaks.

What is CANF's market cap?

Can Fite Biopharma Ltd ADR (CANF) has a market capitalization of $7.28M with a current stock price of $3.18.

Can Fite Biopharma Ltd ADR (CANF)

Official site

HEALTHCARE • BIOTECHNOLOGY • AMEX

$3.18

-0.22 (-6.47%)

Market Cap: $7.28M

Last updated: Sep 01, 2026 at 10:00 AM ET

Earnings

Performance (10Y)

Beat Rate

53%(17/32)

Avg Surprise

-9753.14%

Streak

2 Q

Upcoming Estimates

Mar 31, 2026

EPS Consensus$-1.43

Range$-1.43 - $-1.43

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate Drift

90d ago$-1.26+11.9%

60d ago$-1.26+11.9%

30d ago$-1.43+0.0%

7d ago$-1.43+0.0%

Current$-1.43

Revenue Consensus

Range$0 - $0

0 analysts

Jun 30, 2026

EPS Consensus$-0.51

Range$-0.51 - $-0.51

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate Drift

90d ago$-0.22+56.9%

60d ago$-0.45+11.8%

30d ago$-0.51+0.0%

7d ago$-0.51+0.0%

Current$-0.51

Revenue Consensus

Range$0 - $0

1 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26EST	-	$-0.51	$-0.51 - $-0.51	-	-	1	No revisions (30d)	-
Mar 31, 2026Mar 26EST	-	$-1.43	$-1.43 - $-1.43	-	-	1	No revisions (30d)	-
Dec 31, 2025Dec 25	$N/A	$-2.80	$-2.80 - $-2.80	N/A	Beat	1	0 1 30d	-
Sep 30, 2025Sep 25	$N/A	$-2.80	$-2.80 - $-2.80	N/A	Beat	1	0 1 30d	-
Jun 30, 2025Jun 25	$0.00	N/A	-	+100.00%	Beat	1	0 1 30d	-
Mar 31, 2025Mar 25	$0.00	N/A	-	+100.00%	Beat	1	0 1 30d	-
Dec 31, 2024Dec 24	$N/A	$-0.25	-	N/A	Beat	0	No revisions (30d)	-
Sep 30, 2024Sep 24	$N/A	$-0.24	-	N/A	Beat	-	-	-
Jun 30, 2024Jun 24	$N/A	$-0.22	$-0.22 - $-0.22	N/A	Beat	0	No revisions (30d)	-
Mar 31, 2024Mar 24	$N/A	$-0.52	$-0.52 - $-0.52	N/A	Beat	0	No revisions (30d)	-
Dec 31, 2023Dec 23	$-60.00	$-7.40	$-7.51 - $-7.30	-710.81%	Miss	2	No revisions (30d)	-5303.9%
Sep 30, 2023Sep 23	$-0.44	N/A	-	+94.88%	Beat	2	No revisions (30d)	+99.3%
Jun 30, 2023Jun 23	$-0.42	N/A	-	+97.10%	Beat	1	No revisions (30d)	+47.5%
Mar 31, 2023Mar 23	$-0.65	N/A	-	+98.29%	Beat	2	No revisions (30d)	+27.8%
Dec 31, 2022Dec 22	$-1.11	$-0.09	$-0.91 - $0.49	-1180.62%	Miss	3	No revisions (30d)	+63.0%
Sep 30, 2022Sep 22	$-60.00	$-21.00	$-21.03 - $-20.96	-185.71%	Miss	3	No revisions (30d)	+0.0%
Jun 30, 2022Jun 22	$-0.80	N/A	-	+95.29%	Beat	-	-	+98.7%
Mar 31, 2022Mar 22	$-0.90	N/A	-	+96.79%	Beat	2	1 0 30d	+25.0%
Dec 31, 2021Dec 21	$-3.00	$-1.80	$-1.80 - $-1.80	-66.67%	Miss	1	No revisions (30d)	+0.0%
Sep 30, 2021Sep 21	$-60.00	$-0.90	$-0.90 - $-0.90	-6566.67%	Miss	2	No revisions (30d)	-25.6%
Jun 30, 2021Jun 21	$-60.00	$-10.67	$-10.69 - $-10.66	-462.32%	Miss	2	No revisions (30d)	+0.0%
Mar 31, 2021Mar 21	$-1.20	N/A	-	+96.84%	Beat	-	-	+99.3%
Dec 31, 2020Dec 20	$-3.00	$-2.10	$-2.11 - $-2.09	-42.86%	Miss	2	No revisions (30d)	-588.9%
Sep 30, 2020Sep 20	$-47.78	$-48.00	$-48.01 - $-48.00	+0.46%	Beat	2	No revisions (30d)	+73.5%
Jun 30, 2020Jun 20	$-60.00	$-72.00	$-72.03 - $-71.97	+16.67%	Beat	2	No revisions (30d)	+75.0%
Mar 31, 2020Mar 20	$-180.00	$-118.00	-	-52.54%	Miss	-	-	+25.0%
Dec 31, 2019Dec 19	$-0.44	N/A	-	+51.07%	Beat	1	No revisions (30d)	+84.3%
Sep 30, 2019Sep 19	$-180.00	$-156.00	$-156.15 - $-155.85	-15.38%	Miss	2	No revisions (30d)	-133828.6%
Jun 30, 2019Jun 19	$-240.00	$-330.00	-	+27.27%	Beat	-	-	-33.3%
Mar 31, 2019Mar 19	$-240.00	$-390.00	-	+38.46%	Beat	-	-	+20.0%
Dec 31, 2018Dec 18	$-2.78	$-0.07	$-0.07 - $-0.07	-3871.43%	Miss	0	No revisions (30d)	+73.5%
Sep 30, 2018Sep 18	$-0.13	$-0.06	$-0.06 - $-0.06	-124.00%	Miss	0	No revisions (30d)	+99.9%
Jun 30, 2018Jun 18	$-180.00	$-0.06	$-0.06 - $-0.06	-299900.00%	Miss	1	1 0 30d	+0.0%
Mar 31, 2018Mar 18	$-300.00	$-240.00	$-240.00 - $-239.99	-25.00%	Miss	2	No revisions (30d)	-150.0%
Dec 31, 2017Dec 17	$-10.50	$-9.00	$-9.01 - $-8.99	-16.67%	Miss	2	No revisions (30d)	-900.0%
Sep 30, 2017Sep 17	$-120.00	N/A	-	+66.67%	Beat	-	-	+55.6%
Jun 30, 2017Jun 17	$-180.00	$-270.00	-	+33.33%	Beat	-	-	-
Mar 31, 2017Mar 17	$-120.00	N/A	-	+55.56%	Beat	-	-	-
Dec 31, 2016Dec 16	$-1.05	N/A	-	+90.00%	Beat	-	-	-
Sep 30, 2016Sep 16	$-270.00	$-195.00	-	-38.46%	Miss	-	-	-

Dividends

Dividend Metrics

Yield0.00%

Annual/Share$0.00

No dividend payments in the selected period.

Key Metrics

Valuation
P/E Ratio	-0.00	EV/EBITDA	0.10x
Price/FCF	-114.85x	FCF Yield	-0.87%
Profitability
Profit Margin	0.00%	Operating Margin	-2489.00%
ROE	-178.20%	ROIC	-139.17%
Financial Health
Debt/Equity	0.01x	Interest Coverage	N/A
Current Ratio	3.46x	Quick Ratio	3.46x
Trading Statistics
Beta	-0.04	Avg Volume	34.20K
52-Week High	$13.40	52-Week Low	$2.56

Technical Indicators Dashboard

Moving Averages

SMA 10$3.35

SMA 20$3.36

SMA 50$3.31

SMA 200$3.97

EMA 10$3.34

EMA 20$3.34

EMA 50$3.32

EMA 200$5.67

MACD

Line: 0.01Signal: 0.02Hist: -0.02

ADX

ADX: 32.1+DI: 19.4-DI: 17.8

Aroon & PSAR

Aroon Up32.0

Aroon Down20.0

PSAR$3.66

Bollinger Bands

Upper Band$3.59

Lower Band$3.14

%B Position1349%(Upper)

Band Width0.09

RSI (14-Day)

Neutral

43.3

Momentum Oscillators

Stoch %K31.7

Stoch %D35.1

Williams %R-95.2

ROC (10d)-11.2%

Momentum-0.40

CCI (20d)-127.2

MFI (14d)49.3

Volatility Measures

ATR (14d)$0.17(5.4%)

StdDev (20d)0.11

Hist Vol64.3%(High)

Volume Flow

VWAP$3.24

OBV591.7M

AD Line90.6B

CMF (20d)0.033

Volume Metrics

Avg Vol (20d)34.3K

Vol Ratio1.4x

VWMA (20d)$3.41

Pivot Points

R3$3.52

R2$3.46

R1$3.43

Pivot Point$3.37

S1$3.34

S2$3.28

S3$3.25

Advanced Oscillators

TSI0.99

Ultimate Osc36.3

KST18.48

Financial Data

Quarter	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Total Revenue	$101,500	$101,500	$101,000	$101,000	$179,000	$179,000	$158,000	$158,000	$155,000	$196,000	$196,000	$196,000
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$101,500	$101,500	$101,000	$101,000	$179,000	$179,000	$158,000	$158,000	$155,000	$196,000	$196,000	$196,000

Operating Expenses	$2.63M	$2.63M	$2.55M	$2.55M	$2.20M	$2.20M	$2.21M	$2.21M	$1.99M	$2.06M	$1.98M	$2.91M
R&D	$1.83M	$1.83M	$1.52M	$1.52M	$1.44M	$1.44M	$1.44M	$1.44M	$1.27M	$1.30M	$1.36M	$2.06M
SG&A	$798,000	$798,000	$1.03M	$1.03M	$761,000	$761,000	$762,500	$762,500	$722,000	$762,000	$624,000	$847,000
Operating Income	$-2,526,000	$-2,526,000	$-2,449,000	$-2,449,000	$-2,017,999	$-2,017,999	$-2,047,000	$-2,047,000	$-1,834,000	$-1,865,000	$-1,784,000	$-2,712,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$14,000	$3,000	$0	$162,000
Income Before Tax	$-2,476,000	$-2,476,000	$-2,438,000	$-2,438,000	$-1,961,500	$-1,961,500	$-1,978,500	$-1,978,500	$-1,652,000	$-1,762,000	$-1,670,000	$-2,550,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$-3,750	$-3,500	$-4,000	$-162,000

Net Income	$-2,476,000	$-2,476,000	$-2,438,000	$-2,438,000	$-1,961,500	$-1,961,500	$-1,978,500	$-1,978,500	$-1,652,000	$-1,762,000	$-1,670,000	$-2,388,000

EBITDA	$-2,525,500	$-2,525,500	$-2,437,500	$-2,437,500	$-2,015,000	$-2,015,000	$-2,046,500	$-2,046,500	$-1,830,250	$-1,861,500	$-1,780,000	$-2,708,500
EBIT	$-2,526,000	$-2,526,000	$-2,449,000	$-2,449,000	$-2,017,999	$-2,017,999	$-2,047,000	$-2,047,000	$-1,834,000	$-1,865,000	$-1,784,000	$-2,712,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CANF

News

CANF Forecast — Price Target — Prediction for 2027

The article provides a price target for Can-Fite Biopharma Ltd (CANF) for 2027, indicating a target of 8.00 based on one analyst's forecast. It also touches upon analyst ratings, EPS, and revenue metrics, while emphasizing that the information is not investment advice.

TradingView•Aug 19, 2026 2:10 AM8/19/26•

Neutral

Can-Fite Gains on Test Findings

Can-Fite BioPharma Ltd. (CANF) saw its shares rise after announcing new preclinical findings. These findings indicate that its drug, namodenoson, enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer, providing support for an upcoming Phase IIb study. The combination increased cell death, suggesting namodenoson weakens cancer cell survival mechanisms.

Baystreet.ca•Aug 17, 2026 4:41 PM8/17/26•

Bullish

Can-Fite's namodenoson boosts gemcitabine potency in pancreatic cancer preclinical models

New preclinical data indicates that Can-Fite BioPharma's namodenoson enhances the efficacy of gemcitabine in pancreatic cancer cells by boosting pro-apoptotic effects. These findings support the design of a planned Phase IIb combination study for advanced pancreatic adenocarcinoma. Namodenoson, an A3 adenosine receptor agonist, is thought to suppress survival pathways in cancer cells, making them more susceptible to chemotherapy.

AllSci•Aug 17, 2026 4:11 PM8/17/26•

Somewhat-Bullish

Can-Fite Gains on Test Findings

Can-Fite BioPharma Ltd. saw its shares rise after announcing new preclinical findings. These findings show that its drug, namodenoson, enhances the anti-cancer effects of gemcitabine chemotherapy in pancreatic cancer. This research supports the design of Can-Fite's upcoming Phase IIb study for advanced pancreatic adenocarcinoma.

Baystreet.ca•Aug 17, 2026 3:11 PM8/17/26•

Bullish

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer. These findings provide mechanistic support for the design of Can-Fite’s planned Phase IIb study, which will evaluate namodenoson in combination with gemcitabine and additional standard-of-care therapy in patients with advanced pancreatic adenocarcinoma. The company noted that namodenoson increased the level of a protein central to cell death and weakened the survival mechanisms of cancer cells.

GlobeNewswire•Aug 17, 2026 11:13 AM8/17/26•

Bullish

Frequently Asked Questions About CANF

Does CANF pay dividends?: Can Fite Biopharma Ltd ADR (CANF) has a dividend payment track record. See the CANF dividend history page for its current payment status, yield, and streaks.
What is CANF's market cap?: Can Fite Biopharma Ltd ADR (CANF) has a market capitalization of $7.28M with a current stock price of $3.18.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In